{"id":112437,"date":"2025-09-03T15:00:00","date_gmt":"2025-09-03T14:00:00","guid":{"rendered":"https:\/\/en.econostrum.info\/uk\/?p=112437"},"modified":"2025-09-03T12:30:40","modified_gmt":"2025-09-03T11:30:40","slug":"pip-list-178-conditions-749-monthly-payment","status":"publish","type":"post","link":"https:\/\/en.econostrum.info\/uk\/pip-list-178-conditions-749-monthly-payment\/","title":{"rendered":"Full PIP List: 178 Conditions That Qualify You for Up to \u00a3749 Monthly Payment"},"content":{"rendered":"\n

The Department for Work and Pensions (DWP) has unveiled a comprehensive list of 178 medical conditions<\/strong> that qualify individuals for Personal Independence Payments (PIP). This crucial benefit aims to assist those with long-term physical or mental health conditions, disabilities, or learning difficulties, helping them maintain independence and ease the financial burden of daily living expenses.<\/p>\n\n\n\n

As of April 2025, there are more than 3.7 million<\/strong> PIP claims in the UK, reflecting a growing need for financial support among people with a variety of medical conditions. The government\u2019s latest data shows that eligible claimants could receive up to \u00a3749<\/strong> every four weeks, depending on their circumstances, making it a vital lifeline for many. <\/p>\n\n\n\n

The Role of Personal Independence Payment<\/strong><\/h2>\n\n\n\n

Personal Independence Payment (PIP<\/a>) provides essential support to those living with long-term conditions that significantly affect their daily lives<\/strong>. Unlike other welfare benefits, PIP is not means-tested, meaning claimants do not need to demonstrate financial need to qualify. The amount received depends on the level of care and mobility support required, with higher payments available for those who need more intensive assistance.<\/p>\n\n\n\n

According to the most recent data released by the DWP, eligible individuals can receive weekly payments of either \u00a373.90<\/strong> or \u00a3110.40<\/strong> for the daily living component, and either \u00a329.20<\/strong> or \u00a377.05<\/strong> for the mobility component. If a claimant qualifies for both enhanced components, they could receive a maximum of \u00a3749.80<\/strong> every four weeks. These payments are crucial for helping individuals maintain their independence, particularly as they approach State Pension <\/a>age.<\/p>\n\n\n\n

178 Conditions Now Eligible for PIP<\/strong><\/h2>\n\n\n\n

The DWP\u2019s list of 178 qualifying conditions includes a broad range of both physical and mental health issues. Among the most common are mixed anxiety and depressive disorders<\/strong> (407,024 claims), osteoarthritis<\/strong> (285,604 claims), and autistic spectrum disorders<\/strong> (225,344 claims). <\/p>\n\n\n\n

Other notable conditions include chronic pain syndromes<\/strong> (179,774 claims), epilepsy<\/strong> (67,839 claims), and breast cancer<\/strong> (27,792 claims). Here is the full list of the 178 medical conditions qualifying for PIP:<\/p>\n\n\n\n

    \n
  • Mixed anxiety and depressive disorders \u2013 407,024<\/li>\n\n\n\n
  • Osteoarthritis \u2013 285,604<\/li>\n\n\n\n
  • Autistic spectrum disorders \u2013 225,344<\/li>\n\n\n\n
  • Specific back pain \u2013 210,415<\/li>\n\n\n\n
  • Inflammatory arthritis \u2013 186,071<\/li>\n\n\n\n
  • Chronic pain syndromes \u2013 179,774<\/li>\n\n\n\n
  • Global learning disability \u2013 170,746<\/li>\n\n\n\n
  • Mood disorders \u2013 146,983<\/li>\n\n\n\n
  • Psychotic disorders \u2013 128,324<\/li>\n\n\n\n
  • Chronic obstructive pulmonary disease (COPD) \u2013 90,282<\/li>\n\n\n\n
  • Cerebrovascular disease \u2013 85,621<\/li>\n\n\n\n
  • Hyperkinetic disorder \u2013 83,187<\/li>\n\n\n\n
  • Epilepsy \u2013 67,839<\/li>\n\n\n\n
  • Anxiety disorders \u2013 61,737<\/li>\n\n\n\n
  • Stress reactions \u2013 61,572<\/li>\n\n\n\n
  • Other neurological disorders \u2013 59,954<\/li>\n\n\n\n
  • Multiple sclerosis \u2013 56,254<\/li>\n\n\n\n
  • Personality disorder \u2013 56,047<\/li>\n\n\n\n
  • Injuries\/fractures\/dislocations \u2013 51,497<\/li>\n\n\n\n
  • Non-specific back pain \u2013 48,978<\/li>\n\n\n\n
  • Pancreatic disease \u2013 41,142<\/li>\n\n\n\n
  • Cerebral palsy \u2013 39,916<\/li>\n\n\n\n
  • Specific learning disorder \u2013 36,207<\/li>\n\n\n\n
  • Neuropathy \u2013 30,779<\/li>\n\n\n\n
  • Movement disorders \u2013 29,767<\/li>\n\n\n\n
  • Ischaemic heart disease \u2013 29,284<\/li>\n\n\n\n
  • Breast cancer \u2013 27,792<\/li>\n\n\n\n
  • Cognitive disorders \u2013 26,858<\/li>\n\n\n\n
  • Asthma \u2013 24,813<\/li>\n\n\n\n
  • Sensorineural hearing loss \u2013 24,684<\/li>\n\n\n\n
  • Head injury \u2013 24,355<\/li>\n\n\n\n
  • Knee disorders \u2013 22,544<\/li>\n\n\n\n
  • Cancers of the gastrointestinal tract \u2013 22,317<\/li>\n\n\n\n
  • Genetic disorders, dysplasias, and malformations \u2013 22,225<\/li>\n\n\n\n
  • Hip disorders \u2013 19,644<\/li>\n\n\n\n
  • Cancers of the genitourinary tract \u2013 18,339<\/li>\n\n\n\n
  • Wrist and hand disorders \u2013 18,020<\/li>\n\n\n\n
  • Diseases of the retina and optic nerve \u2013 18,000<\/li>\n\n\n\n
  • Neck disorders \u2013 17,841<\/li>\n\n\n\n
  • Cancers of the haematological system \u2013 17,748<\/li>\n\n\n\n
  • Amputations \u2013 17,506<\/li>\n\n\n\n
  • Substance use disorders \u2013 16,817<\/li>\n\n\n\n
  • Inflammatory bowel disease \u2013 16,465<\/li>\n\n\n\n
  • Ankle and foot disorders \u2013 15,321<\/li>\n\n\n\n
  • Visual field defects \u2013 15,200<\/li>\n\n\n\n
  • Other generalised musculoskeletal diseases \u2013 14,740<\/li>\n\n\n\n
  • Cardiac failure \u2013 14,584<\/li>\n\n\n\n
  • Other regional musculoskeletal diseases \u2013 14,528<\/li>\n\n\n\n
  • Spinal cord compression \u2013 14,501<\/li>\n\n\n\n
  • Cancers of the respiratory tract \u2013 13,022<\/li>\n\n\n\n
  • Other diseases affecting vision \u2013 12,596<\/li>\n\n\n\n
  • Viral diseases \u2013 12,407<\/li>\n\n\n\n
  • Metabolic and endocrine disorders \u2013 12,404<\/li>\n\n\n\n
  • Kidney disease \u2013 11,458<\/li>\n\n\n\n
  • Obsessive-compulsive disorder \u2013 11,208<\/li>\n\n\n\n
  • Cardiac arrhythmias \u2013 10,426<\/li>\n\n\n\n
  • Shoulder disorders \u2013 10,320<\/li>\n\n\n\n
  • Other cardiovascular diseases \u2013 9,613<\/li>\n\n\n\n
  • Diseases of blood vessels\/lymphatics \u2013 9,086<\/li>\n\n\n\n
  • Headache \u2013 9,008<\/li>\n\n\n\n
  • Unknown primary \u2013 8,783<\/li>\n\n\n\n
  • Renal failure \u2013 8,163<\/li>\n\n\n\n
  • Benign tumours \u2013 8,092<\/li>\n\n\n\n
  • Spina bifida \u2013 8,047<\/li>\n\n\n\n
  • Systemic lupus erythematosus \u2013 7,988<\/li>\n\n\n\n
  • Eating disorders \u2013 7,894<\/li>\n\n\n\n
  • Non-epileptic disturbance of consciousness \u2013 7,729<\/li>\n\n\n\n
  • Diseases of the ovary, uterus, cervix, vagina, and vulva \u2013 7,081<\/li>\n\n\n\n
  • Diseases of collagen and elastic tissue \u2013 6,816<\/li>\n\n\n\n
  • Brain and spinal cord cancer \u2013 6,742<\/li>\n\n\n\n
  • Muscle disease \u2013 6,588<\/li>\n\n\n\n
  • Peripheral arterial disease \u2013 6,332<\/li>\n\n\n\n
  • Mixed hearing loss \u2013 6,182<\/li>\n\n\n\n
  • Muscular dystrophy \u2013 6,077<\/li>\n\n\n\n
  • Unknown or missing \u2013 6,013<\/li>\n\n\n\n
  • Other diseases affecting hearing and balance \u2013 5,870<\/li>\n\n\n\n
  • Peripheral nerve injury \u2013 5,645<\/li>\n\n\n\n
  • Hypertension \u2013 5,541<\/li>\n\n\n\n
  • Cirrhosis \u2013 5,475<\/li>\n\n\n\n
  • Infections \u2013 5,381<\/li>\n\n\n\n
  • Congenital heart disease \u2013 5,326<\/li>\n\n\n\n
  • Vasculitis \u2013 5,017<\/li>\n\n\n\n
  • Peripheral venous disease \u2013 4,947<\/li>\n\n\n\n
  • Papulosquamous and inflammatory rashes \u2013 4,676<\/li>\n\n\n\n
  • Ataxia \u2013 4,597<\/li>\n\n\n\n
  • Upper respiratory tract diseases \u2013 4,582<\/li>\n\n\n\n
  • Granulomatous lung disease \u2013 4,342<\/li>\n\n\n\n
  • Obesity \u2013 4,256<\/li>\n\n\n\n
  • Cardiomyopathy \u2013 4,150<\/li>\n\n\n\n
  • Other gastrointestinal diseases \u2013 4,044<\/li>\n\n\n\n
  • Diseases of the oesophagus, stomach, and duodenum \u2013 3,994<\/li>\n\n\n\n
  • Thyroid disease \u2013 3,968<\/li>\n\n\n\n
  • Degenerative neuronal diseases \u2013 3,950<\/li>\n\n\n\n
  • Glaucoma \u2013 3,871<\/li>\n\n\n\n
  • Other lower respiratory tract diseases \u2013 3,774<\/li>\n\n\n\n
  • Aneurysm \u2013 3,476<\/li>\n\n\n\n
  • Other autoimmune disease \u2013 3,455<\/li>\n\n\n\n
  • Valve disease \u2013 3,167<\/li>\n\n\n\n
  • Colon diseases \u2013 3,162<\/li>\n\n\n\n
  • Cystic fibrosis \u2013 3,106<\/li>\n\n\n\n
  • Haemolytic disorders \u2013 3,064<\/li>\n\n\n\n
  • Skin cancers \u2013 3,060<\/li>\n\n\n\n
  • Pancreas diseases \u2013 2,982<\/li>\n\n\n\n
  • Irritable bowel syndrome \u2013 2,910<\/li>\n\n\n\n
  • Liver failure \u2013 2,780<\/li>\n\n\n\n
  • Diseases of the conjunctiva, cornea, eyelids, and lacrimal apparatus \u2013 2,744<\/li>\n\n\n\n
  • Conductive hearing loss \u2013 2,674<\/li>\n\n\n\n
  • Bronchiectasis \u2013 2,660<\/li>\n\n\n\n
  • Crystal deposition disorders \u2013 2,649<\/li>\n\n\n\n
  • Hydrocephalus \u2013 2,564<\/li>\n\n\n\n
  • Eye movement disorders \u2013 2,489<\/li>\n\n\n\n
  • Small bowel diseases \u2013 2,270<\/li>\n\n\n\n
  • Other skin diseases \u2013 2,193<\/li>\n\n\n\n
  • Fracture complications \u2013 2,051<\/li>\n\n\n\n
  • Cancers of bone \u2013 2,030<\/li>\n\n\n\n
  • Abdominal hernias \u2013 1,936<\/li>\n\n\n\n
  • Multisystem \u2013 1,930<\/li>\n\n\n\n
  • Somatoform and dissociative disorders \u2013 1,872<\/li>\n\n\n\n
  • Diseases of the bladder, urethra, prostate, testes, and penis \u2013 1,823<\/li>\n\n\n\n
  • Cataract \u2013 1,765<\/li>\n\n\n\n
  • Pulmonary fibrosis \u2013 1,748<\/li>\n\n\n\n
  • Urinary incontinence \u2013 1,725<\/li>\n\n\n\n
  • Clotting disorders \u2013 1,680<\/li>\n\n\n\n
  • Blood disorders \u2013 1,653<\/li>\n\n\n\n
  • Anaemia \u2013 1,529<\/li>\n\n\n\n
  • Pulmonary embolus \u2013 1,490<\/li>\n\n\n\n
  • Adrenal disease \u2013 1,457<\/li>\n\n\n\n
  • Sjogren\u2019s syndrome \u2013 1,382<\/li>\n\n\n\n
  • Bacterial diseases \u2013 1,346<\/li>\n\n\n\n
  • Elbow disorders \u2013 1,190<\/li>\n\n\n\n
  • Antiphospholipid syndrome \u2013 1,187<\/li>\n\n\n\n
  • Osteonecrosis and osteochondritis \u2013 1,179<\/li>\n\n\n\n
  • Infections and parasites \u2013 1,170<\/li>\n\n\n\n
  • Systemic sclerosis \u2013 1,168<\/li>\n\n\n\n
  • Conduct disorder \u2013 1,166<\/li>\n\n\n\n
  • Diseases of the rectum and anus \u2013 1,115<\/li>\n\n\n\n
  • Hypothalamic and pituitary disease \u2013 1,104<\/li>\n\n\n\n
  • Other sarcomas \u2013 989<\/li>\n\n\n\n
  • Chronic hepatitis \u2013 983<\/li>\n\n\n\n
  • Other psychiatric disorders of childhood \u2013 925<\/li>\n\n\n\n
  • Disease of gallbladder and biliary tract \u2013 912<\/li>\n\n\n\n
  • Refractive errors \u2013 759<\/li>\n\n\n\n
  • Burns \u2013 728<\/li>\n\n\n\n
  • Other endocrine diseases \u2013 718<\/li>\n\n\n\n
  • Hypersensitivity diseases \u2013 714<\/li>\n\n\n\n
  • Other genitourinary disease \u2013 682<\/li>\n\n\n\n
  • Uveitis \u2013 675<\/li>\n\n\n\n
  • Other diseases of the immune system \u2013 674<\/li>\n\n\n\n
  • Infectious diseases of the respiratory tract \u2013 652<\/li>\n\n\n\n
  • Other metabolic diseases \u2013 635<\/li>\n\n\n\n
  • Liver transplantation \u2013 624<\/li>\n\n\n\n
  • Injuries – Visual \u2013 603<\/li>\n\n\n\n
  • Other cancers \u2013 593<\/li>\n\n\n\n
  • Disease of the pleura \u2013 586<\/li>\n\n\n\n
  • Platelet disorders \u2013 572<\/li>\n\n\n\n
  • Other infectious diseases \u2013 563<\/li>\n\n\n\n
  • Bullous disease \u2013 559<\/li>\n\n\n\n
  • Metabolic red cell disorders \u2013 444<\/li>\n\n\n\n
  • Benign tumours of bone \u2013 400<\/li>\n\n\n\n
  • Parathyroid disease \u2013 367<\/li>\n\n\n\n
  • Inborn errors of metabolism \u2013 311<\/li>\n\n\n\n
  • Congenital disorders of the GI tract \u2013 304<\/li>\n\n\n\n
  • Heart transplantation \u2013 291<\/li>\n\n\n\n
  • Vitreous disease \u2013 252<\/li>\n\n\n\n
  • Pericarditis \u2013 237<\/li>\n\n\n\n
  • Pneumoconiosis \u2013 209<\/li>\n\n\n\n
  • Amyloidosis \u2013 156<\/li>\n\n\n\n
  • Lung transplantation \u2013 144<\/li>\n\n\n\n
  • Hyperlipidaemia \u2013 141<\/li>\n\n\n\n
  • Benign tumours of the gastrointestinal tract \u2013 107<\/li>\n\n\n\n
  • Cancers of the adrenal gland \u2013 103<\/li>\n\n\n\n
  • Extremes of age \u2013 69<\/li>\n\n\n\n
  • Faecal soiling (encopresis) \u2013 63<\/li>\n\n\n\n
  • Porphyria \u2013 57<\/li>\n\n\n\n
  • Heart and lung transplantation \u2013 44<\/li>\n\n\n\n
  • Enuresis \u2013 40<\/li>\n\n\n\n
  • Factitious disorder \u2013 23<\/li>\n\n\n\n
  • Protozoal diseases \u2013 16<\/li>\n<\/ul>\n\n\n\n

    The inclusion of so many conditions underscores the importance of PIP as a flexible support system designed to assist a wide range of people facing long-term challenges. This financial assistance plays a critical role in enabling individuals to maintain autonomy and access the necessary resources to manage their conditions. By expanding eligibility to cover a wider spectrum of conditions, the government ensures that more people receive the financial assistance they need to live independently. <\/p>\n","protected":false},"excerpt":{"rendered":"

    The Department for Work and Pensions has revealed the full list of 178 medical conditions that qualify for Personal Independence Payment (PIP). These payments offer financial support of up to \u00a3749 per month for those with long-term health conditions. The list includes a variety of physical and mental health issues, with eligibility based on the level of care and mobility support required.<\/p>\n","protected":false},"author":10,"featured_media":112439,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[46],"tags":[],"class_list":["post-112437","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-social-welfare","generate-columns","tablet-grid-50","mobile-grid-100","grid-parent","grid-33","no-featured-image-padding"],"_links":{"self":[{"href":"https:\/\/en.econostrum.info\/uk\/wp-json\/wp\/v2\/posts\/112437","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/en.econostrum.info\/uk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/en.econostrum.info\/uk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/en.econostrum.info\/uk\/wp-json\/wp\/v2\/users\/10"}],"replies":[{"embeddable":true,"href":"https:\/\/en.econostrum.info\/uk\/wp-json\/wp\/v2\/comments?post=112437"}],"version-history":[{"count":3,"href":"https:\/\/en.econostrum.info\/uk\/wp-json\/wp\/v2\/posts\/112437\/revisions"}],"predecessor-version":[{"id":114450,"href":"https:\/\/en.econostrum.info\/uk\/wp-json\/wp\/v2\/posts\/112437\/revisions\/114450"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/en.econostrum.info\/uk\/wp-json\/wp\/v2\/media\/112439"}],"wp:attachment":[{"href":"https:\/\/en.econostrum.info\/uk\/wp-json\/wp\/v2\/media?parent=112437"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/en.econostrum.info\/uk\/wp-json\/wp\/v2\/categories?post=112437"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/en.econostrum.info\/uk\/wp-json\/wp\/v2\/tags?post=112437"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}